ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > SOME Biogen chatter

<< Previous

Bullboard Posts

Next >>

Comment by retiredcopon May 28, 2021 8:55am

179 Views

Post# 33284817

RE:SOME Biogen chatter

A hugely consequential decision:' How Biogen's Alzheimer's drug came to face the FDA
By June 7, the regulator will decide on whether to approve aducanumab, a decision that could have far-reaching consequences for patients, Biogen and Alzheimer's research.
Published May 27, 2021

https://www.biopharmadive.com/news/biogen-aducanumab-alzheimers-fda-drug-review/600897/

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China